Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy-Reference-Cited by-同舟云学术

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy

Published:2015-09 Issue:9 Volume:26 Page:1948-1953
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Blackwell K.,Semiglazov V.,Krasnozhon D.,Davidenko I.,Nelyubina L.,Nakov R.,Stiegler G.,Singh P.,Schwebig A.,Kramer S.,Harbeck N.

Funder

Sandoz GmbH

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/9/1948/16701481/mdv281.pdf

Reference18 articles.

1. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours;Aapro;Eur J Cancer,2011

2. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain—results of the LEARN Study;Almenar;Eur J Cancer Care (Engl),2009

3. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines;Falandry;Eur J Cancer,2010

4. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice;Barni;Med Oncol,2014

5. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice;Weycker;Breast Cancer Res Treat,2012

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of G-CSF in the prevention of cytostaticassociated adverse events during antitumor drug therapy;Meditsinskiy sovet = Medical Council;2024-07-25

2. Filgrastim biosimilar (EP2006): A review of 15 years’ post-approval evidence;Critical Reviews in Oncology/Hematology;2024-04

3. Validation of Nivestym compared to Neupogen: An NMDP analysis;Journal of Clinical Apheresis;2023-12

4. Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting;BMJ Open;2023-11

5. Effectiveness and Safety of Originator and Biosimilar G-CSF as Primary Prophylaxis in DLBCL: A Cohort Study and Meta-Analysis;2023-09-11